Yearly STL Archives: 2011

Acne is a common dermatological condition found in about 85% of adolescents and young adults. Acne can have significant psychological, social or physical impacts. This article delves into the importance of patinet adherence and therapeutic strategies.

Update on drugs, approval dates, and comments. Spinosad 0.9% cream rinse (Natroba™), Light emitting diode (LED) skin rejuvenation system (Tanda™ Professional Rejuvenate), Voclosporin Voclera™ (ISA247) are covered.

Vulvovaginal diseases commonly are inadequately diagnosed and treated. This article discusses the important role dermatologists play in identifying irregular presentations, recognizing skin problems, and addressing itch, pain, and inflammation.

Acitretin over the last 20 years has proven useful in a number of dermatologic diseases. Evidence of efficacy, side-effect profile, and approach to its use will be reviewed.

Update on drugs, approval dates, and comments. Human papillomavirus quadrivalent (Types 6, 11, 16, and 18) recombinant vaccine (Gardasil®), Daptomycin for injection (Cubicin®) are covered.

An overview and update of skin conditions and treatments introduced in 2010: Quick overview of drug name, indications and regulatory status. Adapalene 0.1% lotion (Differin®), Clindamycin phosphate 1.2% + tretinoin 0.025% gel (Veltin™) and many other drugs are covered.

A variety of novel therapeutic modalities have recently become available for patients with cutaneous T cell lymphoma (CTCL). Here, we offer a brief overview of these agents and discuss their place in the spectrum of current therapies for CTCL.

Drug Treatments for Skin Disease Introduced in 2010. Adapalene 0.1% lotion (Differin®), Drospirenone / ethinyl estradiol / levomefolate calcium + levomefolate calcium tablets (Beyaz™) and many other drugs are covered.

Genital herpes is a common sexually transmitted infection caused by the herpes simplex virus (HSV). This article discusses an overview of HSV, diagnosis and workup, as well as treatment options for management of genital herpes.

Psoriasis is a chronic inflammatory cutaneous disorder that can significantly affect patient quality of life (QoL). This article discusses immunologic abnormalities, immune mediators, and the possible pathogenesis of psoriasis.

Psoriasis and eczema, especially atopic eczema, are two of the most common cutaneous conditions seen by family physicians and dermatologists. This article focuses on corticosteroids of varying strengths and their suggested indications.

Update on drugs, approval dates, and comments. Calcipotriene/Calcipotriol0.005% foam (Sorilux™), Ceftaroline fosamil (Teflaro™) are covered as well as an update on Health Canada on the use of tacrolimus (Protopic®) for atopic dermatitis.

Topical therapy forms the cornerstone of treatment in the management of psoriasis. Topical options, vehicle advances, and treatment efficacy of several topicals are discussed for managing psoriasis.

Epidermal growth factor receptor (EGFR) inhibitors are an increasingly important treatment option for metastasized cancer in patients. We present an overview of the various cutaneous side-effects associated with EGFR inhibition and discuss their respective therapeutic options.